Synchron Raises $200 Million for Stentrode Platform Commercialisation
Synchron has secured $200 million in a Series D funding round to accelerate the commercial launch of its Stentrode brain-computer interface (BCI) platform and to support the development of next-generation interfaces.
Funding Round Details
The investment round was led by Double Point Ventures, with participation from ARCH Ventures, Bezos Expeditions, Khosla Ventures, METIS, and NTI.
New investors joining this round include the Australian National Reconstruction Fund (NRF), Qatar Investment Authority (QIA), T.Rx Capital, K5 Global, IQT, and Protocol Labs.
Use of Funds and Future Plans
- Expedite key clinical studies
- Expand the multidisciplinary team
“We’ve built the first non-surgical brain-computer interface designed for everyday life for people with paralysis,” said Synchron founder and CEO Tom Oxley.
“This funding brings us closer to commercialising the Stentrode BCI platform, while accelerating development of a major breakthrough in the field – a next-generation, transcatheter high-channel whole-brain interface.”
Industry Impact
Synchron’s advancements represent a significant breakthrough in brain-computer interface technology, aiming to improve quality of life for people with paralysis through a minimally invasive, practical solution.
Author’s Summary
Synchron’s $200 million funding marks a key milestone toward commercializing its pioneering non-surgical brain-computer interface and advancing next-gen neural technologies.